Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Merck Drug Patent Portfolio

Merck owns 32 orange book drugs protected by 155 US patents with Pifeltro having the least patent protection, holding only 1 patent. And Janumet Xr with maximum patent protection, holding 12 patents. Given below is the list of Merck's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12358870 30 Jun, 2042
Active
US10603282 Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine 29 Nov, 2036
Active
US10842751 Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine 29 Nov, 2036
Active
US9908845 Aryl ethers and uses thereof 05 Sep, 2034
Active
US9969689 Aryl ethers and uses thereof 05 Sep, 2034
Active
USRE49948 Aryl ethers and uses thereof 05 Sep, 2034
Active
US10098892 Solid dosage formulations of an orexin receptor antagonist 29 May, 2033
Active
US11980623 Solid dosage formulations of an orexin receptor antagonist 29 May, 2033
Active
US8487093 β-lactamase inhibitors 21 Mar, 2033
Active
US10603384 Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative 28 Feb, 2033
Active
US9493582 Alkylated cyclodextrin compositions and processes for preparing and using the same 27 Feb, 2033
Active
US9604948 Process for preparing substituted 5-fluoro-1H-pyrazolopyridines 26 Nov, 2032
Active
US8486975 Non-nucleoside reverse transcriptase inhibitors 30 Aug, 2032
Active
US10772888 Solid pharmaceutical compositions containing an integrase inhibitor 30 Mar, 2032
Active
US9023790 Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin 04 Jul, 2031
Active
US9358297 Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin 24 Jun, 2031
Active
US10736896 Substituted 5-fluoro-1H-pyrazolopyridines and their use 19 May, 2031
Active
US11439642 Substituted 5-fluoro-1H-pyrazolopyridines and their use 19 May, 2031
Active
US8420656 Substituted 5-fluoro-1H-pyrazolopyridines and their use 19 May, 2031
Active
US8921377 Substituted 5-fluoro-1H-pyrazolopyridines and their use 19 May, 2031
Active
US9993476 Substituted 5-flouro-1H-pyrazolopyridines and their use 19 May, 2031
Active
US8871759 Inhibitors of hepatitis C virus replication 04 May, 2031
Active
US9649311 Solid pharmaceutical compositions containing an integrase inhibitor 21 Apr, 2031
Active
US9649311 Solid pharmaceutical compositions containing an integrase inhibitor 21 Oct, 2030
Active
US9308204 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives 21 Oct, 2030
Active
US9439902 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives 21 Oct, 2030
Active
US9439901 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives 21 Oct, 2030
Active
US8080580 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives 13 Jul, 2030
Active
US8771733 Pharmaceutical composition containing an anti-nucleating agent 02 Jun, 2030
Active
US7951797 Substituted diazepan orexin receptor antagonists 20 Nov, 2029
Active
US7754731 Potassium salt of an HIV integrase inhibitor 11 Sep, 2029
Active
US7973040 Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors 24 Jul, 2029
Active
US10117951 Sulfoalkyl ether cyclodextrin compositions 13 Mar, 2029
Active
US8410077 Sulfoalkyl ether cyclodextrin compositions 13 Mar, 2029
Active
US9750822 Sulfoalkyl ether cyclodextrin compositions 13 Mar, 2029
Active
US7754731 Potassium salt of an HIV integrase inhibitor 11 Mar, 2029
Active
US8414921 Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin 21 Jan, 2029
Active
USRE46791 Substituted dihydroquinazolines 18 Jan, 2029
Active
US8414921 Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin 21 Jul, 2028
Active
US8450372 Formulations of suberoylanilide hydroxamic acid and methods for producing same 18 Mar, 2028
Active
US8852632 Pharmaceutical formulation containing a release rate controlling composition 28 Jan, 2028
Active
US7772178 Pharmaceutical formulations and methods of treatment using the same 11 Nov, 2027
Active
US8258132 Pharmaceutical composition of a tachykinin receptor antagonist 26 Sep, 2027
Active
US7326708 Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor 24 May, 2027
Active
US8119602 Administration of HCV protease inhibitors in combination with food to improve bioavailability 17 Mar, 2027
Active
US7456219 Polymorphs of suberoylanilide hydroxamic acid 11 Mar, 2027
Active
US7326708 Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor 24 Nov, 2026
Active
USRE44733 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block 27 Jul, 2026
Active
US8093295 Formulations of suberoylanilide hydroxamic acid and methods for producing the same 16 May, 2026
Active
USRE44733 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block 27 Jan, 2026
Active
US7399787 Methods of treating cancer with HDAC inhibitors 09 Feb, 2025 Expired
USRE43298 Peptides as NS3-serine protease inhibitors of hepatitis C virus 22 Dec, 2024 Expired
US7196086 Substituted dihydroquinazolines 22 May, 2024 Expired
US8513255 Substituted dihydroquinazolines 22 May, 2024 Expired
US7169780 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 03 Apr, 2024 Expired
US7851509 Polymorphs of suberoylanilide hydroxamic acid 21 Feb, 2024 Expired
US7169780 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 03 Oct, 2023 Expired
US6987108 Pharmaceutical formulations of antineoplastic agents and processes of making and using the same 08 Sep, 2023 Expired
US7820660 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 25 Apr, 2023 Expired
US7217713 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Apr, 2023 Expired
US7435734 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Apr, 2023 Expired
US7652069 Polymorphs of suberoylanilide hydroxamic acid 04 Mar, 2023 Expired
US7732490 Methods of treating cancer 04 Mar, 2023 Expired
US8067472 Methods of treating Hodgkin's and non-Hodgkin's lymphoma 04 Mar, 2023 Expired
US8101663 Polymorphs of suberoylanilide hydroxamic acid 04 Mar, 2023 Expired
US7786118 Pharmaceutical formulations of antineoplastic agents 21 Feb, 2023 Expired
US8623868 Processes of making and using pharmaceutical formulations of antineoplastic agents 21 Feb, 2023 Expired
US6699871 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jan, 2023 Expired
US7125873 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jan, 2023 Expired
US7217713 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Oct, 2022 Expired
US7435734 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Oct, 2022 Expired
US6699871 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jul, 2022 Expired
US7125873 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jul, 2022 Expired
US8168637 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of diabetes 26 Jun, 2022 Expired
US6689761 Combination therapy for HIV infection 10 Feb, 2021 Expired
US6949527 6-Mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block 27 Jan, 2021 Expired
US7265009 HDP-CVD methodology for forming PMD layer 07 Aug, 2020 Expired
US7265099 Use of chemical chelators as reversal agents for drug-induced neuromuscular block 07 Aug, 2020 Expired
US5691336 Morpholine compounds are prodrugs useful as tachykinin receptor antagonists 04 Sep, 2019 Expired
US5661151 Tetrahydrofuran antifungals 19 Jul, 2019 Expired
US5691336 Morpholine compounds are prodrugs useful as tachykinin receptor antagonists 04 Mar, 2019 Expired
US6890898 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019 Expired
US7078381 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019 Expired
US7459428 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019 Expired
US5994329 Method for inhibiting bone resorption 17 Jan, 2019 Expired
US6015801 Method for inhibiting bone resorption 17 Jan, 2019 Expired
US6225294 Method for inhibiting bone resorption 17 Jan, 2019 Expired
US6514520 Stabilized antihistamine syrup 01 Dec, 2018 Expired
US5994329 Method for inhibiting bone resorption 17 Jul, 2018 Expired
US6015801 Method for inhibiting bone resorption 17 Jul, 2018 Expired
US6225294 Method for inhibiting bone resorption 17 Jul, 2018 Expired
US6096742 Polymorphic form of a tachykinin receptor antagonist 01 Jul, 2018 Expired
US6514520 Stabilized antihistamine syrup 01 Jun, 2018 Expired
US6172046 Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection 21 Mar, 2018 Expired
US6472373 Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection 21 Mar, 2018 Expired
US6645961 Dry granulation formulation for an HIV protease inhibitor 04 Mar, 2018 Expired
US5952323 Carbapenem antibiotic 15 Nov, 2017 Expired
US6063811 Compositions for a once day treatment of cyclooxygenase-2 mediated diseases 06 Nov, 2017 Expired
US5952300 Antifungal compositions 28 Sep, 2017 Expired
US6136783 Antifungal compositions 28 Sep, 2017 Expired
US6172046 Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection 21 Sep, 2017 Expired
US6472373 Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection 21 Sep, 2017 Expired
US5952323 Carbapenem antibiotic 15 May, 2017 Expired
US6063811 Compositions for a once day treatment of cyclooxygenase-2 mediated diseases 06 May, 2017 Expired
US6177074 Polyethylene glycol modified interferon therapy 01 May, 2017 Expired
US6461605 Continuous low-dose cytokine infusion therapy 01 May, 2017 Expired
US6524570 Polyethylene glycol modified interferon therapy 01 May, 2017 Expired
US6303661 Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals 24 Apr, 2017 Expired
US5952300 Antifungal compositions 28 Mar, 2017 Expired
US6136783 Antifungal compositions 28 Mar, 2017 Expired
US6177074 Polyethylene glycol modified interferon therapy 01 Nov, 2016 Expired
US6461605 Continuous low-dose cytokine infusion therapy 01 Nov, 2016 Expired
US6524570 Polyethylene glycol modified interferon therapy 01 Nov, 2016 Expired
US6340475 Extending the duration of drug release within the stomach during the fed mode 19 Sep, 2016 Expired
US6635280 Extending the duration of drug release within the stomach during the fed mode 19 Sep, 2016 Expired
US5478820 Antibiotic compounds 21 May, 2016 Expired
US5478820 Antibiotic compounds 21 Nov, 2015 Expired
US5691374 Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors 18 Nov, 2015 Expired
US5807825 Platelet aggregation inhibitors 15 Sep, 2015 Expired
US5514650 Aza cyclohexapeptide compounds 26 Jul, 2015 Expired
US7211582 Methods for treating urticaria using descarboethoxyloratadine 30 Jun, 2015 Expired
US7214683 Compositions of descarboethoxyloratadine 30 Jun, 2015 Expired
US7214684 Methods for the treatment of allergic rhinitis 30 Jun, 2015 Expired
US5968902 Platelet aggregation inhibitors 02 Jun, 2015 Expired
US5691374 Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors 18 May, 2015 Expired
US5747447 Stable polypeptide composition 05 May, 2015 Expired
US5719147 Morpholine and thiomorpholine tachykinin receptor antagonists 17 Apr, 2015 Expired
US5716942 Treatment of migraine with morpholine tachykinin receptor antagonists 10 Feb, 2015 Expired
US5514650 Aza cyclohexapeptide compounds 26 Jan, 2015 Expired
US7211582 Methods for treating urticaria using descarboethoxyloratadine 30 Dec, 2014 Expired
US7214683 Compositions of descarboethoxyloratadine 30 Dec, 2014 Expired
US7214684 Methods for the treatment of allergic rhinitis 30 Dec, 2014 Expired
US5462932 Oral liquid alendronate formulations 17 Nov, 2014 Expired
US5686570 Platelet aggregation inhibitors 11 Nov, 2014 Expired
US5756451 Platelet aggregation inhibitors 11 Nov, 2014 Expired
US5703079 Tetrahydrofuran antifungals 26 Aug, 2014 Expired
US5462932 Oral liquid alendronate formulations 17 May, 2014 Expired
US5512570 Treatment of emesis with morpholine tachykinin receptor antagonists 04 Mar, 2014 Expired
US5260291 Tetrazine derivatives 11 Feb, 2014 Expired
US5474995 Phenyl heterocycles as cox-2 inhibitors 24 Dec, 2013 Expired
US6239173 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor 24 Dec, 2013 Expired
USRE38506 Potent inducers of terminal differentiation and methods of use thereof 29 Nov, 2013 Expired
US5378804 Aza cyclohexapeptide compounds 16 Sep, 2013 Expired
US5792746 Aza cyclohexapeptide compounds 16 Sep, 2013 Expired
US5260291 Tetrazine derivatives 11 Aug, 2013 Expired
US5652233 Antibiotic compounds 02 Aug, 2013 Expired
US7342005 Antibiotic compounds 02 Aug, 2013 Expired
US5538982 Medical use for tachykinin antagonists 23 Jul, 2013 Expired
US5474995 Phenyl heterocycles as cox-2 inhibitors 24 Jun, 2013 Expired
US6239173 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor 24 Jun, 2013 Expired
US5378804 Aza cyclohexapeptide compounds 16 Mar, 2013 Expired
US5792746 Aza cyclohexapeptide compounds 16 Mar, 2013 Expired
US5652233 Antibiotic compounds 02 Feb, 2013 Expired
US7342005 Antibiotic compounds 02 Feb, 2013 Expired
US7214692 Medical use for tachykinin antagonists 18 Sep, 2012 Expired


Given below is the list of recent legal activities going on the following drug patents of Merck.

Activity Date Patent Number
Patent litigations
transaction for FDA Determination of Regulatory Review Period 27 Jun, 2024 US8080580
transaction for FDA Determination of Regulatory Review Period 27 Jun, 2024 US8080580
transaction for FDA Determination of Regulatory Review Period 27 Jun, 2024 US8080580
Expire Patent
Critical
03 Jun, 2024 US8168637
Email Notification
Critical
01 May, 2024 US10603384
Payment of Maintenance Fee, 8th Year, Large Entity 30 Apr, 2024 US9493582
Email Notification
Critical
30 Apr, 2024 US10603384
Patent eCofC Notification 30 Apr, 2024 US10603384
Recordation of Patent eCertificate of Correction 30 Apr, 2024 US10603384
Mail Patent eCofC Notification 30 Apr, 2024 US10603384
Maintenance Fee Reminder Mailed
Critical
29 Apr, 2024 US8263600
Court Processing Terminated 17 Apr, 2024 US7326708 (Litigated)
Court Processing Terminated 17 Apr, 2024 US7326708 (Litigated)
Court Processing Terminated 17 Apr, 2024 US7326708 (Litigated)
Court Processing Terminated 17 Apr, 2024 US7326708 (Litigated)


Merck's Drug Patent Litigations

Merck's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Mar 22, 2001, against patent number US6689761. The petitioner , challenged the validity of this patent, with CHODAKEWITZ et al as the respondent. Click below to track the latest information on how companies are challenging Merck's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7326708 June, 2020 Final Written Decision
(10 May, 2021)
Merck Sharp & Dohme Corp. et al. Sun Pharmaceutical Industries Ltd. et al.
US7326708 June, 2020 Final Written Decision
(10 May, 2021)
Merck Sharp & Dohme Corp. et al. Dr. Reddy's Laboratories, Inc. et al.
US7326708 October, 2019 Final Written Decision
(07 May, 2021)
Merck Sharp & Dohme Corp. et al. Mylan Pharmaceuticals, Inc.
US7326708 June, 2020 Terminated-Settled
(08 Dec, 2020)
Merck Sharp & Dohme Corp. Teva Pharmaceuticals USA, Inc.
US6635280 April, 2014 Final Written Decision
(21 Sep, 2015)
Depomed, Inc. Endo Pharmaceutical Inc. et al.
US6340475 April, 2014 Final Written Decision
(21 Sep, 2015)
Depomed, Inc. Endo Pharmaceutical Inc. et al.
US6635280 January, 2014 Final Written Decision
(08 Jul, 2015)
DepoMed, Inc. Purdue Pharma L.P.
US6635280 January, 2014 FWD Entered
(08 Jul, 2015)
DepoMed, Inc. Purdue Pharma L.P.
US6340475 January, 2014 Final Written Decision
(08 Jul, 2015)
Depomed, Inc. Purdue Pharma L.P.
US6340475 January, 2014 FWD Entered
(08 Jul, 2015)
Depomed, Inc. Purdue Pharma L.P.
US5691336 December, 2014 Terminated-Denied
(25 Jun, 2015)
Merck Sharp & Dohme Corp. Apotex Inc.
US5691336 December, 2014 Institution Denied
(25 Jun, 2015)
Merck Sharp & Dohme Corp. Apotex Inc. et al.
US6340475 April, 2014 Institution Denied
(29 Sep, 2014)
Depomed, Inc. Endo Pharmaceutical Inc. et al.
US6635280 April, 2014 Institution Denied
(29 Sep, 2014)
Depomed, Inc. Endo Pharmaceutical Inc. et al.
US7214692 July, 2005 Decision
(18 Jan, 2006)
Russell Michael Hagan et al
US7214683 December, 2004 Decision
(24 Mar, 2005)
ABERG et al
US6645961 June, 2001 Decision
(27 Mar, 2002)
LUI et al
US6689761 March, 2001 Decision
(25 May, 2001)
CHODAKEWITZ et al


Merck Drug Patents' Oppositions Filed in EPO

Merck drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jun 11, 2008, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP04755691A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP18171672A May, 2022 Ethypharm Granted and Under Opposition
EP18171672A May, 2022 Generics (U.K.) Limited Granted and Under Opposition
EP18171672A May, 2022 Fresenius Kabi Deutschland GmbH Granted and Under Opposition
EP18171672A May, 2022 Aera A/S Granted and Under Opposition
EP16198994A Jan, 2020 Ter Meer Steinmeister & Partner Patentanwälte mbB Granted and Under Opposition
EP16198994A Dec, 2019 Lederer & Keller Patentanwälte Partnerschaft mbB Granted and Under Opposition
EP05852790A Aug, 2017 Georg Kalhammer/Stephan Teipel Patent maintained as amended
EP05852790A Aug, 2017 Ter Meer Steinmeister & Partner Patentanwälte mbB Patent maintained as amended
EP05852839A Aug, 2014 Sölch, Günter Patent maintained as amended
EP03711372A May, 2013 Generics [UK] Limited Revoked
EP05077584A Mar, 2011 APOTEX INC. Revoked
EP02796109A Apr, 2009 Teva Pharmaceutical Industries Ltd. Patent maintained as amended
EP02796109A Apr, 2009 Hexal AG Patent maintained as amended
EP03709188A Mar, 2009 CHEMAGIS LTD. Opposition rejected
EP04755691A Jun, 2008 Teva Pharmaceutical Industries Ltd. Patent maintained as amended


Merck's Family Patents

Merck drugs have patent protection in a total of 64 countries. It's US patent count contributes only to 14.7% of its total global patent coverage. 9 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents





Clinical Trials

Recent Clinical Trials by Merck:

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008) Merck Sharp & Dohme LLC NA COMPLETED
(Jan, 2019)
PHASE2
A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004) Merck Sharp & Dohme LLC NA TERMINATED
(Dec, 2018)
PHASE1
A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014) Merck Sharp & Dohme LLC NA COMPLETED
(Dec, 2018)
PHASE1
A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013) Merck Sharp & Dohme LLC NA COMPLETED
(Dec, 2018)
PHASE1


Merck Drug List

Given below is the complete list of Merck's drugs and the patents protecting them.


1. Belsomra

Belsomra is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10098892 Solid dosage formulations of an orexin receptor antagonist 29 May, 2033
(7 years from now)
Active
US11980623 Solid dosage formulations of an orexin receptor antagonist 29 May, 2033
(7 years from now)
Active
US7951797 Substituted diazepan orexin receptor antagonists 20 Nov, 2029
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Belsomra's drug page


2. Bridion

Bridion is protected by 5 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
USRE44733
(Pediatric)
6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block 27 Jul, 2026
(6 months from now)
Active
USRE44733 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block 27 Jan, 2026
(18 days from now)
Active
US6949527 6-Mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block 27 Jan, 2021
(4 years ago)
Expired
US7265009 HDP-CVD methodology for forming PMD layer 07 Aug, 2020
(5 years ago)
Expired
US7265099 Use of chemical chelators as reversal agents for drug-induced neuromuscular block 07 Aug, 2020
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bridion's drug page


3. Cancidas

Cancidas is protected by 10 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5952300
(Pediatric)
Antifungal compositions 28 Sep, 2017
(8 years ago)
Expired
US6136783
(Pediatric)
Antifungal compositions 28 Sep, 2017
(8 years ago)
Expired
US5952300 Antifungal compositions 28 Mar, 2017
(8 years ago)
Expired
US6136783 Antifungal compositions 28 Mar, 2017
(8 years ago)
Expired
US5514650
(Pediatric)
Aza cyclohexapeptide compounds 26 Jul, 2015
(10 years ago)
Expired
US5514650 Aza cyclohexapeptide compounds 26 Jan, 2015
(10 years ago)
Expired
US5378804
(Pediatric)
Aza cyclohexapeptide compounds 16 Sep, 2013
(12 years ago)
Expired
US5792746
(Pediatric)
Aza cyclohexapeptide compounds 16 Sep, 2013
(12 years ago)
Expired
US5378804 Aza cyclohexapeptide compounds 16 Mar, 2013
(12 years ago)
Expired
US5792746 Aza cyclohexapeptide compounds 16 Mar, 2013
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cancidas's drug page


4. Clarinex

Clarinex is protected by 8 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6514520
(Pediatric)
Stabilized antihistamine syrup 01 Dec, 2018
(7 years ago)
Expired
US6514520 Stabilized antihistamine syrup 01 Jun, 2018
(7 years ago)
Expired
US7211582
(Pediatric)
Methods for treating urticaria using descarboethoxyloratadine 30 Jun, 2015
(10 years ago)
Expired
US7214683
(Pediatric)
Compositions of descarboethoxyloratadine 30 Jun, 2015
(10 years ago)
Expired
US7214684
(Pediatric)
Methods for the treatment of allergic rhinitis 30 Jun, 2015
(10 years ago)
Expired
US7211582 Methods for treating urticaria using descarboethoxyloratadine 30 Dec, 2014
(11 years ago)
Expired
US7214683 Compositions of descarboethoxyloratadine 30 Dec, 2014
(11 years ago)
Expired
US7214684 Methods for the treatment of allergic rhinitis 30 Dec, 2014
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Clarinex's drug page


5. Crixivan

Crixivan is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6689761 Combination therapy for HIV infection 10 Feb, 2021
(4 years ago)
Expired
US6645961 Dry granulation formulation for an HIV protease inhibitor 04 Mar, 2018
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Crixivan's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Delstrigo

Delstrigo is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10603282 Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine 29 Nov, 2036
(10 years from now)
Active
US10842751 Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine 29 Nov, 2036
(10 years from now)
Active
US8486975 Non-nucleoside reverse transcriptase inhibitors 30 Aug, 2032
(6 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Delstrigo's drug page


7. Dutrebis

Dutrebis is protected by 9 patents, out of which 7 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7754731
(Pediatric)
Potassium salt of an HIV integrase inhibitor 11 Sep, 2029
(3 years from now)
Active
US7754731 Potassium salt of an HIV integrase inhibitor 11 Mar, 2029
(3 years from now)
Active
US7169780
(Pediatric)
N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 03 Apr, 2024
(1 year, 9 months ago)
Expired
US7169780 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 03 Oct, 2023
(2 years ago)
Expired
US7820660 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 25 Apr, 2023
(2 years ago)
Expired
US7217713
(Pediatric)
N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Apr, 2023
(2 years ago)
Expired
US7435734
(Pediatric)
N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Apr, 2023
(2 years ago)
Expired
US7217713 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Oct, 2022
(3 years ago)
Expired
US7435734 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Oct, 2022
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dutrebis's drug page


8. Emend

Emend is protected by 9 patents, out of which 8 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8258132 Pharmaceutical composition of a tachykinin receptor antagonist 26 Sep, 2027
(1 year, 8 months from now)
Active
US5691336
(Pediatric)
Morpholine compounds are prodrugs useful as tachykinin receptor antagonists 04 Sep, 2019
(6 years ago)
Expired
US5691336 Morpholine compounds are prodrugs useful as tachykinin receptor antagonists 04 Mar, 2019
(6 years ago)
Expired
US6096742 Polymorphic form of a tachykinin receptor antagonist 01 Jul, 2018
(7 years ago)
Expired
US5719147 Morpholine and thiomorpholine tachykinin receptor antagonists 17 Apr, 2015
(10 years ago)
Expired
US5716942 Treatment of migraine with morpholine tachykinin receptor antagonists 10 Feb, 2015
(10 years ago)
Expired
US5512570 Treatment of emesis with morpholine tachykinin receptor antagonists 04 Mar, 2014
(11 years ago)
Expired
US5538982 Medical use for tachykinin antagonists 23 Jul, 2013
(12 years ago)
Expired
US7214692 Medical use for tachykinin antagonists 18 Sep, 2012
(13 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Emend's drug page


9. Fosamax

Fosamax is protected by 8 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5994329
(Pediatric)
Method for inhibiting bone resorption 17 Jan, 2019
(6 years ago)
Expired
US6015801
(Pediatric)
Method for inhibiting bone resorption 17 Jan, 2019
(6 years ago)
Expired
US6225294
(Pediatric)
Method for inhibiting bone resorption 17 Jan, 2019
(6 years ago)
Expired
US5994329 Method for inhibiting bone resorption 17 Jul, 2018
(7 years ago)
Expired
US6015801 Method for inhibiting bone resorption 17 Jul, 2018
(7 years ago)
Expired
US6225294 Method for inhibiting bone resorption 17 Jul, 2018
(7 years ago)
Expired
US5462932
(Pediatric)
Oral liquid alendronate formulations 17 Nov, 2014
(11 years ago)
Expired
US5462932 Oral liquid alendronate formulations 17 May, 2014
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fosamax's drug page


10. Integrilin

Integrilin is protected by 5 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5807825 Platelet aggregation inhibitors 15 Sep, 2015
(10 years ago)
Expired
US5968902 Platelet aggregation inhibitors 02 Jun, 2015
(10 years ago)
Expired
US5747447 Stable polypeptide composition 05 May, 2015
(10 years ago)
Expired
US5686570 Platelet aggregation inhibitors 11 Nov, 2014
(11 years ago)
Expired
US5756451 Platelet aggregation inhibitors 11 Nov, 2014
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Integrilin's drug page


11. Invanz

Invanz is protected by 8 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5952323
(Pediatric)
Carbapenem antibiotic 15 Nov, 2017
(8 years ago)
Expired
US5952323 Carbapenem antibiotic 15 May, 2017
(8 years ago)
Expired
US5478820
(Pediatric)
Antibiotic compounds 21 May, 2016
(9 years ago)
Expired
US5478820 Antibiotic compounds 21 Nov, 2015
(10 years ago)
Expired
US5652233
(Pediatric)
Antibiotic compounds 02 Aug, 2013
(12 years ago)
Expired
US7342005
(Pediatric)
Antibiotic compounds 02 Aug, 2013
(12 years ago)
Expired
US5652233 Antibiotic compounds 02 Feb, 2013
(12 years ago)
Expired
US7342005 Antibiotic compounds 02 Feb, 2013
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Invanz's drug page


12. Isentress

Isentress is protected by 10 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8771733 Pharmaceutical composition containing an anti-nucleating agent 02 Jun, 2030
(4 years from now)
Active
US7754731
(Pediatric)
Potassium salt of an HIV integrase inhibitor 11 Sep, 2029
(3 years from now)
Active
US7754731 Potassium salt of an HIV integrase inhibitor 11 Mar, 2029
(3 years from now)
Active
US8852632 Pharmaceutical formulation containing a release rate controlling composition 28 Jan, 2028
(2 years from now)
Active
US7169780
(Pediatric)
N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 03 Apr, 2024
(1 year, 9 months ago)
Expired
US7169780 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 03 Oct, 2023
(2 years ago)
Expired
US7217713
(Pediatric)
N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Apr, 2023
(2 years ago)
Expired
US7435734
(Pediatric)
N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Apr, 2023
(2 years ago)
Expired
US7217713 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Oct, 2022
(3 years ago)
Expired
US7435734 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Oct, 2022
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Isentress's drug page


13. Isentress Hd

Isentress Hd is protected by 12 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10772888 Solid pharmaceutical compositions containing an integrase inhibitor 30 Mar, 2032
(6 years from now)
Active
US9649311
(Pediatric)
Solid pharmaceutical compositions containing an integrase inhibitor 21 Apr, 2031
(5 years from now)
Active
US9649311 Solid pharmaceutical compositions containing an integrase inhibitor 21 Oct, 2030
(4 years from now)
Active
US8771733 Pharmaceutical composition containing an anti-nucleating agent 02 Jun, 2030
(4 years from now)
Active
US7754731
(Pediatric)
Potassium salt of an HIV integrase inhibitor 11 Sep, 2029
(3 years from now)
Active
US7754731 Potassium salt of an HIV integrase inhibitor 11 Mar, 2029
(3 years from now)
Active
US7169780
(Pediatric)
N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 03 Apr, 2024
(1 year, 9 months ago)
Expired
US7169780 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 03 Oct, 2023
(2 years ago)
Expired
US7217713
(Pediatric)
N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Apr, 2023
(2 years ago)
Expired
US7435734
(Pediatric)
N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Apr, 2023
(2 years ago)
Expired
US7217713 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Oct, 2022
(3 years ago)
Expired
US7435734 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Oct, 2022
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Isentress Hd's drug page


14. Janumet

Janumet is protected by 12 patents, out of which 8 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8414921
(Pediatric)
Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin 21 Jan, 2029
(3 years from now)
Active
US8414921 Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin 21 Jul, 2028
(2 years from now)
Active
US7326708
(Pediatric)
Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor 24 May, 2027
(1 year, 4 months from now)
Active
US7326708 Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor 24 Nov, 2026
(10 months from now)
Active
US6699871
(Pediatric)
Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jan, 2023
(2 years ago)
Expired
US7125873
(Pediatric)
Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jan, 2023
(2 years ago)
Expired
US6699871 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jul, 2022
(3 years ago)
Expired
US7125873 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jul, 2022
(3 years ago)
Expired
US6890898 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019
(6 years ago)
Expired
US7078381 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019
(6 years ago)
Expired
US7459428 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019
(6 years ago)
Expired
US6303661 Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals 24 Apr, 2017
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Janumet's drug page


15. Janumet Xr

Janumet Xr is protected by 12 patents, out of which 10 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7326708
(Pediatric)
Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor 24 May, 2027
(1 year, 4 months from now)
Active
US7326708 Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor 24 Nov, 2026
(10 months from now)
Active
US6699871
(Pediatric)
Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jan, 2023
(2 years ago)
Expired
US7125873
(Pediatric)
Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jan, 2023
(2 years ago)
Expired
US6699871 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jul, 2022
(3 years ago)
Expired
US7125873 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jul, 2022
(3 years ago)
Expired
US6890898 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019
(6 years ago)
Expired
US7078381 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019
(6 years ago)
Expired
US7459428 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019
(6 years ago)
Expired
US6303661 Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals 24 Apr, 2017
(8 years ago)
Expired
US6340475 Extending the duration of drug release within the stomach during the fed mode 19 Sep, 2016
(9 years ago)
Expired
US6635280 Extending the duration of drug release within the stomach during the fed mode 19 Sep, 2016
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Janumet Xr's drug page


16. Januvia

Januvia is protected by 10 patents, out of which 8 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7326708
(Pediatric)
Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor 24 May, 2027
(1 year, 4 months from now)
Active
US7326708 Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor 24 Nov, 2026
(10 months from now)
Active
US6699871
(Pediatric)
Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jan, 2023
(2 years ago)
Expired
US7125873
(Pediatric)
Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jan, 2023
(2 years ago)
Expired
US6699871 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jul, 2022
(3 years ago)
Expired
US7125873 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jul, 2022
(3 years ago)
Expired
US6890898 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019
(6 years ago)
Expired
US7078381 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019
(6 years ago)
Expired
US7459428 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019
(6 years ago)
Expired
US6303661 Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals 24 Apr, 2017
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Januvia's drug page


17. Juvisync

Juvisync is protected by 11 patents, out of which 9 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7326708
(Pediatric)
Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor 11 Oct, 2026
(9 months from now)
Active
US7326708 Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor 11 Apr, 2026
(3 months from now)
Active
US6699871
(Pediatric)
Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jan, 2023
(2 years ago)
Expired
US7125873
(Pediatric)
Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jan, 2023
(2 years ago)
Expired
US6699871 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jul, 2022
(3 years ago)
Expired
US7125873 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jul, 2022
(3 years ago)
Expired
US8168637 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of diabetes 26 Jun, 2022
(3 years ago)
Expired
US6890898 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019
(6 years ago)
Expired
US7078381 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019
(6 years ago)
Expired
US7459428 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019
(6 years ago)
Expired
US6303661 Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals 24 Apr, 2017
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Juvisync's drug page


18. Noxafil

Noxafil is protected by 8 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9493582 Alkylated cyclodextrin compositions and processes for preparing and using the same 27 Feb, 2033
(7 years from now)
Active
US9023790 Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin 04 Jul, 2031
(5 years from now)
Active
US9358297 Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin 24 Jun, 2031
(5 years from now)
Active
US10117951 Sulfoalkyl ether cyclodextrin compositions 13 Mar, 2029
(3 years from now)
Active
US8410077 Sulfoalkyl ether cyclodextrin compositions 13 Mar, 2029
(3 years from now)
Active
US9750822 Sulfoalkyl ether cyclodextrin compositions 13 Mar, 2029
(3 years from now)
Active
US5661151 Tetrahydrofuran antifungals 19 Jul, 2019
(6 years ago)
Expired
US5703079 Tetrahydrofuran antifungals 26 Aug, 2014
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Noxafil's drug page


19. Pifeltro

Pifeltro is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8486975 Non-nucleoside reverse transcriptase inhibitors 30 Aug, 2032
(6 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pifeltro's drug page


20. Prevymis

Prevymis is protected by 4 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10603384 Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative 28 Feb, 2033
(7 years from now)
Active
USRE46791 Substituted dihydroquinazolines 18 Jan, 2029
(3 years from now)
Active
US7196086 Substituted dihydroquinazolines 22 May, 2024
(1 year, 7 months ago)
Expired
US8513255 Substituted dihydroquinazolines 22 May, 2024
(1 year, 7 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prevymis's drug page


21. Rebetol

Rebetol is protected by 10 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6172046
(Pediatric)
Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection 21 Mar, 2018
(7 years ago)
Expired
US6472373
(Pediatric)
Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection 21 Mar, 2018
(7 years ago)
Expired
US6172046 Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection 21 Sep, 2017
(8 years ago)
Expired
US6472373 Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection 21 Sep, 2017
(8 years ago)
Expired
US6177074
(Pediatric)
Polyethylene glycol modified interferon therapy 01 May, 2017
(8 years ago)
Expired
US6461605
(Pediatric)
Continuous low-dose cytokine infusion therapy 01 May, 2017
(8 years ago)
Expired
US6524570
(Pediatric)
Polyethylene glycol modified interferon therapy 01 May, 2017
(8 years ago)
Expired
US6177074 Polyethylene glycol modified interferon therapy 01 Nov, 2016
(9 years ago)
Expired
US6461605 Continuous low-dose cytokine infusion therapy 01 Nov, 2016
(9 years ago)
Expired
US6524570 Polyethylene glycol modified interferon therapy 01 Nov, 2016
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rebetol's drug page


22. Recarbrio

Recarbrio is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8487093 β-lactamase inhibitors 21 Mar, 2033
(7 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Recarbrio's drug page


23. Segluromet

Segluromet is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9308204 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives 21 Oct, 2030
(4 years from now)
Active
US9439902 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives 21 Oct, 2030
(4 years from now)
Active
US8080580 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives 13 Jul, 2030
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Segluromet's drug page


24. Steglatro

Steglatro is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8080580 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives 13 Jul, 2030
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Steglatro's drug page


25. Steglujan

Steglujan is protected by 10 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9308204 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives 21 Oct, 2030
(4 years from now)
Active
US9439901 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives 21 Oct, 2030
(4 years from now)
Active
US8080580 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives 13 Jul, 2030
(4 years from now)
Active
US7326708
(Pediatric)
Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor 24 May, 2027
(1 year, 4 months from now)
Active
US7326708 Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor 24 Nov, 2026
(10 months from now)
Active
US6699871
(Pediatric)
Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jan, 2023
(2 years ago)
Expired
US6699871 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jul, 2022
(3 years ago)
Expired
US6890898 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019
(6 years ago)
Expired
US7078381 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019
(6 years ago)
Expired
US7459428 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Steglujan's drug page


26. Temodar

Temodar is protected by 5 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6987108 Pharmaceutical formulations of antineoplastic agents and processes of making and using the same 08 Sep, 2023
(2 years ago)
Expired
US7786118 Pharmaceutical formulations of antineoplastic agents 21 Feb, 2023
(2 years ago)
Expired
US8623868 Processes of making and using pharmaceutical formulations of antineoplastic agents 21 Feb, 2023
(2 years ago)
Expired
US5260291
(Pediatric)
Tetrazine derivatives 11 Feb, 2014
(11 years ago)
Expired
US5260291 Tetrazine derivatives 11 Aug, 2013
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Temodar's drug page


27. Verquvo

Verquvo is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9604948 Process for preparing substituted 5-fluoro-1H-pyrazolopyridines 26 Nov, 2032
(6 years from now)
Active
US10736896 Substituted 5-fluoro-1H-pyrazolopyridines and their use 19 May, 2031
(5 years from now)
Active
US11439642 Substituted 5-fluoro-1H-pyrazolopyridines and their use 19 May, 2031
(5 years from now)
Active
US8420656 Substituted 5-fluoro-1H-pyrazolopyridines and their use 19 May, 2031
(5 years from now)
Active
US8921377 Substituted 5-fluoro-1H-pyrazolopyridines and their use 19 May, 2031
(5 years from now)
Active
US9993476 Substituted 5-flouro-1H-pyrazolopyridines and their use 19 May, 2031
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Verquvo's drug page


28. Victrelis

Victrelis is protected by 3 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7772178 Pharmaceutical formulations and methods of treatment using the same 11 Nov, 2027
(1 year, 10 months from now)
Active
US8119602 Administration of HCV protease inhibitors in combination with food to improve bioavailability 17 Mar, 2027
(1 year, 2 months from now)
Active
USRE43298 Peptides as NS3-serine protease inhibitors of hepatitis C virus 22 Dec, 2024
(1 year, 17 days ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Victrelis's drug page


29. Vioxx

Vioxx is protected by 8 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6063811
(Pediatric)
Compositions for a once day treatment of cyclooxygenase-2 mediated diseases 06 Nov, 2017
(8 years ago)
Expired
US6063811 Compositions for a once day treatment of cyclooxygenase-2 mediated diseases 06 May, 2017
(8 years ago)
Expired
US5691374
(Pediatric)
Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors 18 Nov, 2015
(10 years ago)
Expired
US5691374 Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors 18 May, 2015
(10 years ago)
Expired
US5474995
(Pediatric)
Phenyl heterocycles as cox-2 inhibitors 24 Dec, 2013
(12 years ago)
Expired
US6239173
(Pediatric)
3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor 24 Dec, 2013
(12 years ago)
Expired
US5474995 Phenyl heterocycles as cox-2 inhibitors 24 Jun, 2013
(12 years ago)
Expired
US6239173 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor 24 Jun, 2013
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vioxx's drug page


30. Welireg

Welireg is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12358870 30 Jun, 2042
(16 years from now)
Active
US9908845 Aryl ethers and uses thereof 05 Sep, 2034
(8 years from now)
Active
US9969689 Aryl ethers and uses thereof 05 Sep, 2034
(8 years from now)
Active
USRE49948 Aryl ethers and uses thereof 05 Sep, 2034
(8 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Welireg's drug page


31. Zepatier

Zepatier is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8871759 Inhibitors of hepatitis C virus replication 04 May, 2031
(5 years from now)
Active
US7973040 Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors 24 Jul, 2029
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zepatier's drug page


32. Zolinza

Zolinza is protected by 10 patents, out of which 7 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8450372 Formulations of suberoylanilide hydroxamic acid and methods for producing same 18 Mar, 2028
(2 years from now)
Active
US7456219 Polymorphs of suberoylanilide hydroxamic acid 11 Mar, 2027
(1 year, 2 months from now)
Active
US8093295 Formulations of suberoylanilide hydroxamic acid and methods for producing the same 16 May, 2026
(4 months from now)
Active
US7399787 Methods of treating cancer with HDAC inhibitors 09 Feb, 2025
(10 months ago)
Expired
US7851509 Polymorphs of suberoylanilide hydroxamic acid 21 Feb, 2024
(1 year, 10 months ago)
Expired
US7652069 Polymorphs of suberoylanilide hydroxamic acid 04 Mar, 2023
(2 years ago)
Expired
US7732490 Methods of treating cancer 04 Mar, 2023
(2 years ago)
Expired
US8067472 Methods of treating Hodgkin's and non-Hodgkin's lymphoma 04 Mar, 2023
(2 years ago)
Expired
US8101663 Polymorphs of suberoylanilide hydroxamic acid 04 Mar, 2023
(2 years ago)
Expired
USRE38506 Potent inducers of terminal differentiation and methods of use thereof 29 Nov, 2013
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zolinza's drug page


Merck News

Merck & Co. Inc.: The Transformation of a 130-Year-Old Pharmaceutical Leader Focusing on Cancer Treatment

05 Jan, 2026

Merck to Discuss Patent Expirations and Drug Development Plans at JP Morgan Conference...

01 Jan, 2026

FDA Accelerates Approval Process for Two Promising Merck (MRK) Medications - Finviz

30 Dec, 2025

FDA Accelerates Approval Process for Two Promising Merck (MRK) Medications - Yahoo Finance

30 Dec, 2025

See More